AU2005294275B2 - Immunogenic and therapeutic compositions for Streptococcus pyogenes - Google Patents

Immunogenic and therapeutic compositions for Streptococcus pyogenes Download PDF

Info

Publication number
AU2005294275B2
AU2005294275B2 AU2005294275A AU2005294275A AU2005294275B2 AU 2005294275 B2 AU2005294275 B2 AU 2005294275B2 AU 2005294275 A AU2005294275 A AU 2005294275A AU 2005294275 A AU2005294275 A AU 2005294275A AU 2005294275 B2 AU2005294275 B2 AU 2005294275B2
Authority
AU
Australia
Prior art keywords
gas
antigens
fragment
protein
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005294275A
Other languages
English (en)
Other versions
AU2005294275A1 (en
Inventor
Giuliano Bensi
Guido Grandi
Nathalie Norais
Manuel Rodriguez J. Ortega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2005294275A1 publication Critical patent/AU2005294275A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS SRL reassignment NOVARTIS VACCINES AND DIAGNOSTICS SRL Alteration of Name(s) of Applicant(s) under S113 Assignors: NOVARTIS VACCINES AND DIAGNOSTICS INC.
Application granted granted Critical
Publication of AU2005294275B2 publication Critical patent/AU2005294275B2/en
Assigned to GLAXOSMITHKLINE BIOLOGICALS S.A. reassignment GLAXOSMITHKLINE BIOLOGICALS S.A. Request for Assignment Assignors: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2005294275A 2004-10-08 2005-10-11 Immunogenic and therapeutic compositions for Streptococcus pyogenes Ceased AU2005294275B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US61685404P 2004-10-08 2004-10-08
US60/616,854 2004-10-08
US65273605P 2005-02-15 2005-02-15
US60/652,736 2005-02-15
US70112105P 2005-07-21 2005-07-21
US60/701,121 2005-07-21
US70520905P 2005-08-04 2005-08-04
US60/705,209 2005-08-04
PCT/US2005/036009 WO2006042027A2 (en) 2004-10-08 2005-10-11 Immunogenic and therapeutic compositions for streptococcus pyogenes

Publications (2)

Publication Number Publication Date
AU2005294275A1 AU2005294275A1 (en) 2006-04-20
AU2005294275B2 true AU2005294275B2 (en) 2012-09-13

Family

ID=35720938

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005294275A Ceased AU2005294275B2 (en) 2004-10-08 2005-10-11 Immunogenic and therapeutic compositions for Streptococcus pyogenes

Country Status (6)

Country Link
US (1) US7838010B2 (enExample)
EP (1) EP1807446A2 (enExample)
JP (2) JP2008544949A (enExample)
AU (1) AU2005294275B2 (enExample)
CA (1) CA2583803C (enExample)
WO (1) WO2006042027A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
DE60134494D1 (de) * 2000-12-21 2008-07-31 Id Biomedical Corp Antigene aus streptococcus pyogenes und zugehörige dna-fragmente
WO2005002619A2 (en) * 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US7838010B2 (en) 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
US8529911B2 (en) * 2006-07-07 2013-09-10 Intercell Austria Ag Small Streptococcus pyogenes antigens and their use
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0624874D0 (en) 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
EP2173902A4 (en) * 2007-07-03 2013-01-09 Mt Sinai Hospital THERAPEUTICS AND DIAGNOSTICS FOR GROUP A STREPTOKOKKEN
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
GB0721757D0 (en) * 2007-11-06 2007-12-19 Novartis Ag Streptococcus pyogenes classification
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
DK2344523T3 (da) * 2008-09-17 2016-04-18 Glaxosmithkline Biolog Sa Gas-kombinationsvacciner og lægemidler
NZ592368A (en) 2008-11-05 2013-11-29 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
GB0903858D0 (en) * 2009-03-05 2009-04-22 Novartis Ag Diagnosis of disease
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
AU2012271336B2 (en) * 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
JP2017513849A (ja) * 2014-04-15 2017-06-01 グリフィス・ユニバーシティＧｒｉｆｆｉｔｈ Ｕｎｉｖｅｒｓｉｔｙ Ａ群レンサ球菌ワクチン
WO2015169773A2 (en) * 2014-05-07 2015-11-12 Glaxosmithkline Biologicals S.A. Mutants of spy0269
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Ｆｓｂｍ重組蛋白及其用途
US20200181207A1 (en) * 2017-04-26 2020-06-11 Auckland Uniservices Limited Analytical and therapeutic methods and compositions, and uses thereof
CN108379572A (zh) * 2018-01-25 2018-08-10 暨南大学 一种化脓链球菌HtsA蛋白质疫苗以及制备方法和应用
CN110922456B (zh) * 2019-12-28 2023-02-24 重庆艾力彼生物科技有限公司 铜绿假单胞菌疫苗重组蛋白reSBP-ExoU及制备方法和应用
US20240285746A1 (en) * 2021-06-01 2024-08-29 The Regents Of The University Of California Protective vaccine antigen against streptococcal infection
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078907A2 (en) * 2003-03-04 2004-09-16 Intercell Ag Streptococcus pyogenes antigens

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US5098827A (en) 1988-02-26 1992-03-24 The University Of Florida Novel bacterial markers for pathogenic group B streptococci
GB8827038D0 (en) 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
US5354846A (en) 1988-11-18 1994-10-11 Michael Kehoe Streptolysin O antigen derivatives, its production and uses
DE68929323T2 (de) 1988-12-16 2002-04-18 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
GB2233977B (en) 1989-01-04 1993-03-31 Michael Kehoe Cytolytic streptolysin o mutants and uses
US6737521B1 (en) 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
US5821088A (en) 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
US5391712A (en) 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5378620A (en) 1991-08-30 1995-01-03 Beckman Instruments, Inc. Streptolysin O derivatives
DE4240056A1 (de) 1992-11-28 1994-06-01 Boehringer Mannheim Gmbh Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper
ES2217258T3 (es) 1993-02-01 2004-11-01 Beckman Coulter Inc Factor mitogeno, gen del mismo y procedimiento para su microdeteccion.
DE69433107T2 (de) 1993-06-23 2004-07-08 Beckman Coulter, Inc., Fullerton Rekombinante dnase b aus streptococcus pyogenes
US5585098A (en) 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
CA2201616A1 (en) 1994-10-07 1996-04-18 Vincent A. Fischetti Enzyme for cleavage of the anchor region of surface proteins from gram positive bacteria
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
US5799981A (en) * 1995-05-12 1998-09-01 Global Healthcomm, Inc. Pharmaceutical marketing device and system
DE69619586T2 (de) * 1995-05-18 2002-09-05 Canon K.K., Tokio/Tokyo Verfahren und Vorrichtung zur Bildverarbeitung
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
US5819228A (en) * 1995-10-31 1998-10-06 Utilimed, Inc. Health care payment system utilizing an intensity adjustment factor applied to provider episodes of care
US6014634A (en) * 1995-12-26 2000-01-11 Supermarkets Online, Inc. System and method for providing shopping aids and incentives to customers through a computer network
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6346392B1 (en) 1996-11-27 2002-02-12 Smithkline Beecham Corporation Polynucleotides encoding a novel glutamine transport ATP-binding protein
US6272481B1 (en) * 1996-05-31 2001-08-07 Lucent Technologies Inc. Hospital-based integrated medical computer system for processing medical and patient information using specialized functional modules
IES960488A2 (en) 1996-07-03 1997-11-19 Trinity College Dublin Subunit Vaccine for Streptococcus Equi
EP0821070A1 (en) 1996-07-22 1998-01-28 Carelli, Claude Marcel Henri Pit-1 gene polymorphism and trait selection in animals
PT942983E (pt) 1996-10-31 2007-02-28 Human Genome Sciences Inc Antigénios e vacinas de streptococcus pneumoniae
JP2001510989A (ja) 1996-11-01 2001-08-07 スミスクライン・ビーチャム・コーポレイション 新規コーディング配列
US7033765B1 (en) 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6256614B1 (en) * 1997-04-17 2001-07-03 Jeff H. Wecker Internet system for producing electronic reward cards
CA2289116A1 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
EP1003875B1 (en) 1997-09-12 2006-12-27 University of Tennessee Research Foundation Group a streptococcal vaccines
US6406883B1 (en) 1997-09-26 2002-06-18 Luetticken Rudolf Lmb gene of Streptococcus agalactiae
WO1999016882A1 (en) 1997-09-26 1999-04-08 Medimmune, Inc. LMB GENE OF $i(STREPTOCOCCUS AGALACTIAE)
US6035276A (en) * 1997-10-17 2000-03-07 Veritas Medical Services, Inc. Medical practitioner credentialing system
PT1023435E (pt) 1997-10-17 2007-01-31 Nestle Sa Nova espécie de bactéria láctica
WO1999026969A1 (en) 1997-11-21 1999-06-03 University Of Otago Zoocin a immunity factor
CA2315880A1 (en) 1997-12-31 1999-07-15 Stressgen Biotechnologies Corporation Streptococcal heat shock proteins of the hsp60 family
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
WO1999042588A2 (en) 1998-02-20 1999-08-26 Biochem Pharma Inc. Group b streptococcus antigens
GB9808327D0 (en) 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
US6660520B2 (en) 1998-06-05 2003-12-09 Smithkline Beecham Corporation Nrde
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
US6936252B2 (en) 1998-07-27 2005-08-30 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US6076525A (en) * 1999-01-28 2000-06-20 Hoffman; Michael D. Frame for prone surgical positioning
US7101692B2 (en) 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
US6833356B1 (en) 1999-08-25 2004-12-21 Medimmune, Inc. Pneumococcal protein homologs and fragments for vaccines
AU7721500A (en) 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
WO2001070955A2 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AU7227001A (en) 2000-07-06 2002-01-21 Shire Biochem Inc Streptococcus pyogenes antigens
DK1320542T3 (da) 2000-08-08 2007-09-10 St Jude Childrens Res Hospital Gruppe B streptokokpolypeptider-nukleinsyrer og terapeutiske sammensætninger og vacciner deraf
US7160547B2 (en) 2000-10-10 2007-01-09 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
WO2002057315A2 (en) 2000-10-10 2002-07-25 University Of Tennessee Research Corporation Streptococcal streptolysin s vaccines
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US20070128229A1 (en) 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
US20040236072A1 (en) 2001-04-13 2004-11-25 Olmsted Stephen Bruce Surface proteins of streptococcus pyogenes
CA2881980A1 (en) 2001-05-18 2002-11-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20060073530A1 (en) 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
GB2385274B (en) 2002-02-13 2004-04-14 Ming-Jeng Shue Vaginal suppository delivery device
US20050181388A1 (en) 2002-04-02 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
AU2003213949A1 (en) 2002-04-08 2003-10-27 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
WO2004018646A2 (en) 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
WO2004041157A2 (en) 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
TW566366U (en) 2002-09-27 2003-12-11 Wus Tech Co Ltd Labor-saving portable battery equipment for power-driven walking assisted scooter
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
CN101864431A (zh) 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
AU2003904237A0 (en) 2003-08-08 2003-08-21 Garvan Institute Of Medical Research Novel translocation assay
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
WO2005076010A2 (en) 2004-02-06 2005-08-18 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
AU2005335216A1 (en) 2004-10-05 2007-02-15 Wyeth Probe arrays for detecting multiple strains of different species
US7838010B2 (en) 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
AU2005319174A1 (en) 2004-12-22 2006-06-29 J. Craig Venter Institute, Inc. Group B Streptococcus
EP1770171A1 (en) 2005-09-29 2007-04-04 Universität Zu Köln DNA microarray for rapid identification of Candida albicans in blood cultures.
US8529911B2 (en) 2006-07-07 2013-09-10 Intercell Austria Ag Small Streptococcus pyogenes antigens and their use
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078907A2 (en) * 2003-03-04 2004-09-16 Intercell Ag Streptococcus pyogenes antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Uniprot, accession number Q7CNQ7, 5 July 2004. *
Uniprot, accession number Q8P318, 1 October 2002. *

Also Published As

Publication number Publication date
CA2583803C (en) 2014-11-25
US20090117113A1 (en) 2009-05-07
CA2583803A1 (en) 2006-04-20
WO2006042027A8 (en) 2006-11-02
AU2005294275A1 (en) 2006-04-20
US7838010B2 (en) 2010-11-23
WO2006042027A3 (en) 2006-08-24
JP2012126742A (ja) 2012-07-05
WO2006042027A2 (en) 2006-04-20
JP2008544949A (ja) 2008-12-11
EP1807446A2 (en) 2007-07-18

Similar Documents

Publication Publication Date Title
AU2005294275B2 (en) Immunogenic and therapeutic compositions for Streptococcus pyogenes
US8377446B2 (en) Serum resistance factors of gram positive bacteria
AU2009334428B2 (en) Combination gas vaccines and therapeutics
US8039005B2 (en) Mutant forms of streptolysin O
US9102741B2 (en) GAS57 mutant antigens and GAS57 antibodies
AU2013203022B2 (en) GAS57 mutant antigens and GAS57 antibodies
AU2013203063A1 (en) Combination gas vaccines and therapeutics

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

Free format text: FORMER OWNER(S): NOVARTIS VACCINES AND DIAGNOSTICS SRL

MK14 Patent ceased section 143(a) (annual fees not paid) or expired